Patient characteristics at baseline
| . | TBI + Chemo + PBSCT, no. (%), n = 376 . |
|---|---|
| Age, y | |
| Median | 48.3 |
| Minimum | 16.2 |
| Maximum | 60.5 |
| Sex | |
| Males | 243 (65) |
| Females | 133 (35) |
| Hispanic | |
| Yes | 25 (7) |
| No | 351 (93) |
| Race | |
| White | 346 (92) |
| Black | 17 (5) |
| Other | 10 (3) |
| Unknown | 3 (1) |
| Histology | |
| Low | 61 (16) |
| Intermediate/high | 315 (84) |
| Induction and salvage therapy response | |
| Induction therapy CR or PR followed by relapse, then CR or PR to salvage therapy (sensitive) | 277 (74) |
| Induction therapy CR or PR followed by relapse, but no response to salvage therapy (resistant) | 52 (14) |
| No response to induction therapy (resistant) | 47 (12) |
| . | TBI + Chemo + PBSCT, no. (%), n = 376 . |
|---|---|
| Age, y | |
| Median | 48.3 |
| Minimum | 16.2 |
| Maximum | 60.5 |
| Sex | |
| Males | 243 (65) |
| Females | 133 (35) |
| Hispanic | |
| Yes | 25 (7) |
| No | 351 (93) |
| Race | |
| White | 346 (92) |
| Black | 17 (5) |
| Other | 10 (3) |
| Unknown | 3 (1) |
| Histology | |
| Low | 61 (16) |
| Intermediate/high | 315 (84) |
| Induction and salvage therapy response | |
| Induction therapy CR or PR followed by relapse, then CR or PR to salvage therapy (sensitive) | 277 (74) |
| Induction therapy CR or PR followed by relapse, but no response to salvage therapy (resistant) | 52 (14) |
| No response to induction therapy (resistant) | 47 (12) |